<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002328</url>
  </required_header>
  <id_info>
    <org_study_id>058J</org_study_id>
    <secondary_id>066-167S</secondary_id>
    <nct_id>NCT00002328</nct_id>
  </id_info>
  <brief_title>Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs</brief_title>
  <official_title>Oral/Intravenous Azithromycin in the Treatment of Cryptosporidiosis in Patients Whose Disease Has Not Been Controlled by Conventional Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To provide azithromycin for the treatment of individual patients with proven&#xD;
      cryptosporidiosis whose disease has persisted or progressed despite prior therapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cryptosporidiosis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Cryptosporidiosis infection.&#xD;
&#xD;
          -  Life expectancy of at least 1 week.&#xD;
&#xD;
          -  Failed or been intolerant to prior therapy with standard antidiarrheal or antibiotic&#xD;
             or other therapies for cryptosporidiosis.&#xD;
&#xD;
          -  Consent of parent or guardian for patients under the legal age of consent. Patients&#xD;
             with documented favorable response to azithromycin under Pfizer protocol 066-143 may&#xD;
             receive maintenance therapy under this protocol.&#xD;
&#xD;
        Patients with persistent diarrhea requiring intravenous (IV) fluid therapy to maintain&#xD;
        hydration may receive IV azithromycin after approval by the clinical monitor. Patients&#xD;
        whose disease worsens despite a minimum of 2 weeks of oral therapy or patients whose&#xD;
        disease shows no improvement after 4 weeks of oral therapy will also be considered for a&#xD;
        trial period of intravenous azithromycin.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Known hypersensitivity or significant intolerance to macrolide antibiotics.&#xD;
&#xD;
          -  Eligibility and current treatment at a medical center performing study 066-143,&#xD;
             another study of azithromycin for treatment of cryptosporidiosis in AIDS patients.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Must have failed or been intolerant to prior therapy with standard antidiarrheal or&#xD;
             antibiotic therapies for cryptosporidiosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Day</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pfizer Central Research</name>
      <address>
        <city>Groton</city>
        <state>Connecticut</state>
        <zip>06340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1998</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Antidiarrheals</keyword>
  <keyword>Cryptosporidiosis</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryptosporidiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

